(MENAFNEditorial)
With recently implemented cost-saving measures legislative changes and health insurance reforms the Czech Republic is set to recover from its recent period of stagnancy and decline. Indeed these changes will help to provide for the growing demand for innovative drugs among the country's ageing population. The healthcare spending of the Czech population remains superior to that of the less-developed markets of Eastern and South Eastern Europe demonstrating that demand in these regions will be even higher. In this regard the task of meeting these demands is one that will weigh heavily on the road to recovery.
Headline Expenditure Projections
* Pharmaceuticals: CZK73.34bn (USD3.30bn) in 2014 to CZK75.31bn (USD3.35bn) in 2014; -3.5% in local currency terms and -7.6% in US dollar terms. Forecasts revised upwards from last quarter.
* Healthcare: CZK303.28bn (USD13.66bn) in 2014 to CZK312.52bn (USD13.90bn) in 2015; +3.0% in local currency terms and 1.8% in US dollar terms. Forecasts revised upwards from last quarter.
Full Report Details at
- http://www.fastmr.com/prod/953214_czech_republic_pharmaceuticals_healthcare_report.aspx?afid=101
Risk/Reward Index: Q215 RRI results for the Czech Republic come in with a Reward score of 62.8 out of 100 a Risk score of 64.1 and an overall score of 63.2 - ranking it as the most attractive market in the Central and Eastern European Region. Drugmakers will face challenges in the Czech pharmaceutical market as a result of pricing pressure poor access to the market and increasing generic substitution. Additionally adopted and proposed amendments to healthcare and insurance laws have attracted criticism from the pharmaceutical sector. The Czech pharmaceutical market will nevertheless remain relatively attractive and rewarding due to the regionally high pharmaceutical expenditure per capita compared with its neighbours an ageing population and a favourable urban-rural distribution.
Key Trends And Developments
Czech Republic President Milos Zeman has signed a government amendment to law on public health insurance. The new law which was...
The Czech Republic Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
* Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Czech Republic.
* Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
* Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
* Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
* Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
* Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
* OTC Drug Market: OTC sales (USDbn & % of total sales).
* Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.